5470-24-6

Basic information

• Product Name: 6-Chloro-9-phenyl-9H-purine
• Synonyms: 6-Chloro-9-phenyl-9H-purine
• CAS NO: 5470-24-6
• Molecular Formula: C₁₁H₇ClN₄
• Molecular Weight: 230.65308
• Mol File: 5470-24-6.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 417.5°Cat760mmHg
• Flash Point: 206.3°C
• Appearance: /
• Density: 1.45g/cm³
• Vapor Pressure: 6.31E-08mmHg at 25°C
• Refractive Index: 1.64
• CAS DataBase Reference: 6-Chloro-9-phenyl-9H-purine(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Chloro-9-phenyl-9H-purine(5470-24-6)
• EPA Substance Registry System: 6-Chloro-9-phenyl-9H-purine(5470-24-6)

Safety Data

• Hazardous Substances Data: 5470-24-6(Hazardous Substances Data)

Usage

General Description

6-Chloro-9-phenyl-9H-purine is a chemical compound with the molecular formula C11H7ClN4. It is a derivative of purine, a heterocyclic organic compound. 6-Chloro-9-phenyl-9H-purine has a chloro group at the 6th position and a phenyl group at the 9th position of the purine ring. It has potential applications in the pharmaceutical industry, particularly in the development of new drugs. Its structure and properties make it suitable for further chemical modifications to create novel compounds with potential therapeutic properties. Research on 6-Chloro-9-phenyl-9H-purine and its analogs may lead to the development of new medications for various medical conditions.

InChI:InChI=1/C14H16N2O3/c1-9-10(16-17)8-11(12-4-2-6-18-12)15-14(9)13-5-3-7-19-13/h2-7,9,11,14-15,17H,8H2,1H3/b16-10-

Upstream product

• 41259-65-8 6-chloro-N₄-phenylpyrimidine-4,5-diamine 
• 3724-43-4 Vilsmeier reagent 
• 1483-72-3 diphenyliodonium chloride 
• 87-42-3 6-chloropurine 
• 62-53-3 aniline 
• 64995-55-7 1-phenyl-5-aminoimidazole-4-carboxamide 
• 885619-01-2 ethyl 5-amino-1-phenyl-1H-imidazole-4-carboxylate 
• 98-80-6 phenylboronic acid 
• 6334-42-5 1,9-dihydro-9-phenyl-6H-purin-6-one 

Downstream Products

• 108990-53-0 dimethyl-(9-phenyl-9H-purin-6-yl)-amine 
• 21314-09-0 1,9-dihydro-9-phenyl-6H-purine-6-thione 
• 122625-37-0 methyl-(9-phenyl-9H-purin-6-yl)-amine 
• 135426-10-7 N⁶-(1-phenyl-2(S)-propyl)-9-phenyladenine 
• 135394-15-9 N⁶-(1-phenyl-2(R)-propyl)-9-phenyladenine 
• 62196-39-8 9-phenyl-9H-purine-6-carbonitrile 
• 119980-67-5 9-phenyl-6-phenylethynyl-9H-purine 
• 70386-27-5 N-phenyl-N-(9-phenyl-9H-purin-6-yl)amine 
• 119980-68-6 6-(1-hexynyl)-9-phenyl-9H-purine 
• 135394-13-7 Cyclopentyl-(9-phenyl-9H-purin-6-yl)-amine 
• 119980-70-0 9-phenyl-6-<2-(trimethylsilyl)ethynyl>-9H-purine 
• 20145-09-9 SQ 22517 
• 119980-74-4 6-iodo-9-phenyl-9H-purine 
• 85107-09-1 phenyl(9-phenyl-9H-purin-6-yl)methanone 

Relevant articles and documents

METHOD FOR SYNTHESIZING DIVERSELY SUBSTITUTED PURINES

The present invention relates to a method for synthesizing diversely substituted purines starting from a pyrimidine. Formula (I). The method comprises the formation of an amidine group on the pyrimidine by implementing a Vilsmeier type reagent, the functi

GLUCOSE TRANSPORT INHIBITORS

The present invention relates to chemical compounds of general formula (I): in which RA, RB, RC, RD, m, and n are as given in the description and in the claims, and which effectively and selectively inhibit glucose transporter 1 (GLUT1), to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, as well as to intermediate compounds useful in the preparation of said compounds.

Enhanced selectivity for inhibition of analog-sensitive protein kinases through scaffold optimization

The ability to inhibit any protein kinase of interest with a small molecule is enabled by a combination of genetics and chemistry. Genetics is used to modify the active site of a single kinase to render it distinct from all naturally occurring kinases. Next, organic synthesis is used to develop a small molecule, which does not bind to wild-type kinases but is a potent inhibitor of the engineered kinase. This approach, termed chemical genetics, has been used to generate highly potent mutant kinase-specific inhibitors based on a pyrazolopyrimidine scaffold. Here, we asked if the selectivity of the resulting pyrazolopyrimidines could be improved, as they inhibit several wild-type kinases with low-micromolar IC50 values. Our approach to improve the selectivity of allele-specific inhibitors was to explore a second kinase inhibitor scaffold. A series of 6,9-disubstituted purines was designed, synthesized, and evaluated for inhibitory activity against several kinases in vitro and in vivo. Several purines proved to be potent inhibitors against the analog-sensitive kinases and exhibited greater selectivity than the existing pyrazolopyrimidines.